Tg Therapeutics (TGTX) Net Income towards Common Stockholders (2011 - 2026)

Tg Therapeutics' Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at $19.8 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 289.96% year-over-year to $19.8 million in Q1 2026; TTM through Mar 2026 was $462.3 million, a 879.92% increase from a year earlier, with the FY2025 full-year figure at $447.5 million, up 1323.44% from the prior year.
• Net Income towards Common Stockholders declined to $19.8 million in Q1 2026 per TGTX's latest filing, from $23.4 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $390.9 million in Q3 2025 and bottomed at -$83.8 million in Q4 2022.
• The 5-year median for Net Income towards Common Stockholders is $3.9 million (2024), against an average of $15.1 million.
• Across the five-year window, Net Income towards Common Stockholders plunged 96.6% in 2024 and surged 10005.87% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$83.8 million in 2022, then jumped by 84.1% to -$13.3 million in 2023, then surged by 335.54% to $31.4 million in 2024, then decreased by 25.35% to $23.4 million in 2025, then declined by 15.65% to $19.8 million in 2026.
• Per Business Quant, the three latest TGTX Net Income towards Common Stockholders figures stand at $19.8 million (Q1 2026), $23.4 million (Q4 2025), and $390.9 million (Q3 2025).